article Open AccessTop 1% cited

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Clinical Cancer Research · 2016 · Vol. 22(18) · pp. 4585–4593

Justin F. Gainor✉(Massachusetts General Hospital)Alice T. Shaw(Massachusetts General Hospital)Lecia V. Sequist(Massachusetts General Hospital)Xiujun FuChristopher G. Azzoli(Massachusetts General Hospital)Zofia Piotrowska(Massachusetts General Hospital)Tiffany G. HuynhLing ZhaoLinnea Fulton(Massachusetts General Hospital)Katherine R. Schultz(Massachusetts General Hospital)Emily Howe(Massachusetts General Hospital)Anna F. Farago(Massachusetts General Hospital)Ryan J. Sullivan(Massachusetts General Hospital)James R. StoneSubba R. DigumarthyTeresa MoránAaron N. Hata(Massachusetts General Hospital)Yukako YagiBeow Y. Yeap(Massachusetts General Hospital)Jeffrey A. Engelman(Massachusetts General Hospital)Mari Mino–Kenudson✉

View via DOI Publisher page

Abstract

NSCLCs harboring EGFR mutations or ALK rearrangements are associated with low ORRs to PD-1/PD-L1 inhibitors. Low rates of concurrent PD-L1 expression and CD8(+) TILs within the tumor microenvironment may underlie these clinical observations. Clin Cancer Res; 22(18); 4585-93. ©2016 AACRSee related commentary by Gettinger and Politi, p. 4539.

Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Colorectal Cancer Treatments and StudiesBlockadeLung cancerMedicineCancer researchOncologyCrizotinibInternal medicineBiologyReceptor

MeSH terms

Antineoplastic Agents, ImmunologicalAnaplastic Lymphoma KinaseAdultAgedCarcinoma, Non-Small-Cell LungDNA Mutational AnalysisFemaleGenotypeHumansLung NeoplasmsMaleMiddle AgedMutationTomography, X-Ray ComputedTranslocation, Genetic